Seminars in Oncology
Volume 33, Issue 1 , Pages 139-143 , February 2006

Extravasation of Chemotherapeutic Agents: Prevention and Treatment

  • Tiffany V. Goolsby
    • ,
  • Fredric A. Lombardo

      Affiliations

    • Corresponding Author InformationAddress correspondence to Fredric A. Lombardo, MS, PharmD, College of Pharmacy, Nursing, Allied Health Sciences, Division of Clinical and Administrative Pharmacy Sciences, 2300 4th St NW, Washington, DC 20059

References 

  1. Schrijvers DL . Extravasation (A dreaded complication of chemotherapy) . Ann Oncol . 2003;14(suppl 3):26–30
  2. Schummer W , Schummer C , Muller A , et al.   Extravasation (A rare complication of central venous cannulation? Case report of an imminent erosion of the common carotid artery) . Anaesthesist . 2003;52:711–717
  3. Kassner E . Evaluation and treatment of chemotherapy extravasation injuries . J Pediatr Oncol Nurs . 2000;17:135–148
  4. Oncology Nursing Society (Chemotherapy and Biotherapy Guidelines and Recommendations for Practice) . Pittsburgh, PA: Oncology Nursing Society Publication; 2001;
  5. Schneider SM , Distelhorst CW . Chemotherapy-induced emergencies . Semin Oncol . 1989;16:572–578
  6. Rudolph R , Larson DL . Etiology and treatment of chemotherapeutic agent extravasation injuries (A review) . J Clin Oncol . 1987;5:1116–1126
  7. Bertelli G . Prevention and management of extravasation of cytotoxic drugs . Drug Saf . 1995;12:245–255
  8. Albanell J , Baselga J . Systemic therapy emergencies . Semin Oncol . 2000;27:347–361
  9. Dorr RT . Management of Chemotherapy Extravasation . 2004; Presented at the 8th Annual Making A Difference in Oncology Conference, St Petersburg, FL, April 1–4
  10. Montrose PA . Extravasation management . Semin Oncol Nurs . 1987;3:128–132
  11. Ignoffo RJ , Friedman MA . Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs . Cancer Treat Rev . 1980;7:17–27
  12. Boyle DM , Engelking C . Vesicant extravasations (myths and realities) . Oncol Nurs Forum . 1995;22:57–67
  13. Bomgaars L , Gunawardena S , Kelley SE , et al.   The inactivation of doxorubicin by long ultraviolet light . Cancer Chemother Pharmacol . 1997;40:506–512
  14. Dunagin WG . Clinical toxicity of chemotherapeutic agents (Dermatologic toxicity) . Semin Oncol . 1982;9:14–22
  15. Edward C , Devita VT . Physicians Cancer Chemotherapy Drug Manual . Sudbury, MA: Jones & Bartlett; 2001;
  16. Williams L . The Lippincott Manual of Nursing Practice (Cancer Nursing) . Philadelphia, PA: Lippincott Williams & Wilkins; 2001;
  17. Dorr RT . Pharmacologic management of vesicant of vesicant chemotherapy extravasations . In:  Dorr RT ,  Von Hoff DD editor. Cancer Chemotherapy Handbook . (ed 2). Norwalk, CT: Appleton & Lange; 1994;p. 109–118
  18. Reilly JJ , Neifeld JP , Rosenberg SA . Clinical course and management of accidental adriamycin extravastion . Cancer . 1977;40:2053–2056
  19. Heitman C , Durmus C , Ingianni G . Surgical management after doxorubicin and epirubicin extravasation . J Hand Surg . 1998;23:666–668
  20. Olver IN , Aisner J , Hament A , et al.   A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation . J Clin Oncol . 1988;6:1732–1735
  21. Bertelli G , Gozza A , Forno GB , et al.   Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs (a prospective clinical study) . J Clin Oncol . 1995;13:2851–2855
  22. Saghir NE , Otrock Z , Mufarrij A , et al.   Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing . Lancet Oncol . 2004;5:320–321
  23. Langer SW , Sehested M , Jensen PB . Treatment of anthracycline extravasation with dexrazoxane . Clin Cancer Res . 2000;6:3680–3686
  24. Ulutin HC , Guden M , Dede M , et al.   Comparison of granulocyte-colony, stimulating factor and granulocyte macrophage-colony stimulating factor in the treatment of chemotherapy extravasation ulcers . Eur J Gynaecol Oncol . 2000;21:613–615
  25. Monstrey SJ , Mullick P , Narayanan K , et al.   Hyperbaric oxygen therapy and free radical production (An experimental study in doxorubicin (Adriamycin) extravasation injuries) . Ann Plast Surg . 1997;38:163–168
  26. Akta S , Toklu AS , Olgac V . Hyperbaric oxygen therapy in Adriamycin extravasation (An experimental animal study) . Ann Plast Surg . 2000;45:167–171
  27. Dorr RT , Alberts DS , Stone A . Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse . Cancer Treat Rep . 1985;69:431–437
  28. Patel JS , Krusa M . Distant and delayed mitomycin C extravasation . Pharmacotherapy . 1999;19:1002–1005
  29. Alberts DS , Dorr RT . Case report (Topical DMSO for mitomycin-C-induced skin ulceration) . Oncol Nurs Forum . 1991;18:693–695
  30. Dorr RT . Antidotes to vesicant chemotherapy extravasations . Blood Rev . 1990;4:41–60
  31. Bertelli G , Dini GB , Forno A , et al.   Hyaluronidase as an antidote to extravasation of vinca alkaloids (Clinical results) . J Cancer Res Clin Oncol . 1994;120:505–506
  32. Beri R , Rosen FR , Pacini MJ , et al.   Severe dermatologic reactions at multiple sites after paclitaxel administration . Ann Pharmacother . 2004;38:238–241
  33. Bois AD , Kommoss FGM , Pfisterer J , et al.   Paclitaxel-induced “recall” soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses . Gynecol Oncol . 1996;60:94–96
  34. Dorr RT , Snead K , Liddil JD . Skin ulceration potential of paclitaxel in a mouse skin model in vivo . Cancer . 1996;78:152–156

PII: S0093-7754(05)00437-9

doi: 10.1053/j.seminoncol.2005.11.007

Seminars in Oncology
Volume 33, Issue 1 , Pages 139-143 , February 2006

Article Tools